Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anhui Medical Univ. VEGFR-2 compound 30
- Development stage
- Unknown
- Lead developer
- Anhui Medical University
01
Overview
Anhui Medical Univ. VEGFR-2 compound 30: sourced facts only. name: "Among them, the most potent compound, 30, inhibits VEGFR-2 (IC50 = 1.24 nM) with subtle selectivity over other kinases." [PMID:39353237]; target: "Among them, the most potent compound, 30, inhibits VEGFR-2 (IC50 = 1.24 nM) with subtle selectivity over other kinases." [PMID:39353237]; developer: "Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, School of Pharmacy, Anhui Medical University, Hefei, 230032, Anhui Province, PR China." [PMID:39353237]
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on Anhui Medical Univ. VEGFR-2 compound 30.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anhui Medical Univ. VEGFR-2 compound 30.